InicioRARE • NASDAQ
add
Ultragenyx Pharmaceutical Inc
36,45 $
Preapertura:(0,69 %)+0,25
36,70 $
Cerrados: 9 dic, 5:11:58 GMT-5 · USD · NASDAQ · Renuncia de responsabilidad
Cierre anterior
36,38 $
Intervalo diario
36,22 $ - 39,89 $
Intervalo anual
25,81 $ - 50,00 $
Cap. bursátil
3516,61 M USD
Volumen medio
1,35 M
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos | 159,93 M | 14,65 % |
Gastos operativos | 302,83 M | 20,91 % |
Ingresos netos | -180,41 M | -35,12 % |
Margen de beneficio neto | -112,81 | -17,87 % |
Beneficios por acción | -1,81 | -29,29 % |
EBITDA | -162,28 M | -31,69 % |
Tipo impositivo efectivo | -0,49 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 425,25 M | -30,00 % |
Activos totales | 1190,44 M | -22,62 % |
Responsabilidades totales | 1174,29 M | -0,87 % |
Patrimonio total | 16,16 M | — |
Acciones en circulación | 96,30 M | — |
Precio-valor contable | 363,80 | — |
Rentabilidad económica | -34,22 % | — |
Retorno sobre capital | -44,49 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | sept 2025info | Cambio interanual |
|---|---|---|
Ingresos netos | -180,41 M | -35,12 % |
Efectivo de operaciones | -91,42 M | -36,46 % |
Efectivo de inversión | 117,18 M | 142,53 % |
Efectivo de financiación | 2,00 mil | -99,98 % |
Variación neta del flujo de caja | 26,06 M | 107,89 % |
Flujo de caja libre | -12,35 M | 46,92 % |
Información sobre la empresa
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Director ejecutivo
Fundación
2010
Sitio web
Empleados
1.294
